Clinical Trials Browser

Phase 1 × Lymphoma × dacetuzumab × Clear all

NCT00103779 2014-12-18

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell